Video Upload Options

References

1. Corona A. "A Universal Influenza Vaccine: How Close Are we?" "American Society for Microbiology", 2019 https://www.asm.org/Articles/2019/August/A-Universal-Influenza-Vaccine-How-Close-Are-We
2. Gottlieb, Tanya; Ben-Yedidia, Tamar (2014). "Epitope-based approaches to a universal influenza vaccine". Journal of Autoimmunity (Elsevier BV) 54: 15–20. doi:10.1016/j.jaut.2014.07.005. ISSN 0896-8411. PMID 25172355. https://www.sciencedirect.com/science/article/pii/S0896841114001188. 
3. France, Glenson; Wateska, Angela R; Nowalk, Mary Patricia; DePasse, Jay; Raviotta, Jonathan M; Shim, Eunha; Zimmerman, Richard K; Smith, Kenneth J (1 September 2018). "Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults". Innovation in Aging (Oxford University Press (OUP)) 2 (3): igy035. doi:10.1093/geroni/igy035. ISSN 2399-5300. PMID 30569023.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6293081
4. Sherwood Linda M, Prescott's Microbiology (10th ed.) McGraw-Hill Education , 2017
5. "Universal Influenza Vaccine Tested Successfully In Humans". https://www.sciencedaily.com/releases/2008/01/080124185522.htm. 
6. The Wistar Institute obtains patent for universal flu vaccine technology . Wistar Institute. http://www.wistar.org/news_info/pressreleases/pr_05.06.09.htm
7. NIH Scientists Advance Universal Flu Vaccine. NIH. http://www.nih.gov/news/health/jul2010/niaid-15.htm
8. Shpurer, Sharon (22 April 2007). "Copaxone Inventor Ruth Arnon Taking BiondVax Public" (in en). Haaretz. https://www.haaretz.com/1.4817199. 
9. Dance, Amber (30 March 2012). "News: Moving towards a universal flu vaccine". Nature. doi:10.1038/nature.2012.10333.  https://dx.doi.org/10.1038%2Fnature.2012.10333
10. Immune Targeting Systems – FP01 Influenza, undated page http://www.its-innovation.com/pipeline/fp01-influenza/
11. "Inovio Pharmaceuticals, Inc. Immunizes First Subject In U.S. Influenza DNA Vaccine Clinical Trial". Reuters. https://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=INO×tamp=20100615103000. 
12. "Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial". March 2, 2010. https://www.news-medical.net/news/20100302/Inovio-Biomedicals-SynCon-preventive-DNA-vaccine-receives-approval-in-Korea-for-Phase-I-clinical-trial.aspx. 
13. "Scientific Paper on Inovio Pharmaceuticals SynCon(TM) DNA Vaccines and Intradermal DNA Delivery Technology One of Most Cited Articles in the Journal Vaccine". October 14, 2010. http://www.marketwatch.com/story/scientific-paper-on-inovio-pharmaceuticals-syncontm-dna-vaccines-and-intradermal-dna-delivery-technology-one-of-most-cited-articles-in-the-journal-vaccine-2010-10-14?reflink=MW_news_stmp. 
14. Seattle's Theraclone makes a 'first step' on long road to universal flu vaccine . The Seattle Times. http://seattletimes.nwsource.com/html/localnews/2012228358_flu29m.html
15. VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study. Fierce Biotech. http://www.fiercebiotech.com/press-releases/vaxinnates-universal-flu-vaccine-candidate-shown-safe-and-immunogenic-phase-i-clinica
16. Johnson & Johnson pursues vaccine firm. Charleston Gazette. http://www.allbusiness.com/pharmaceuticals-biotechnology/pharmaceutical-agents/13070919-1.html
17. Immune Targeting Systems – About Us http://www.its-innovation.com/about-us/
18. "FLUTCORE Report Summary". European Commission. http://cordis.europa.eu/result/rcn/167831_en.html. 
19. "Centivax Universal Influenza Vaccine | Grand Challenges". https://gcgh.grandchallenges.org/grant/centivax-universal-influenza-vaccine. 
20. "Influenza vaccines for the future". The New England Journal of Medicine 363 (21): 2036–44. November 2010. doi:10.1056/NEJMra1002842. PMID 21083388.  https://dx.doi.org/10.1056%2FNEJMra1002842
21. "H1N1 Gives Clues to Universal Flu Vaccine". January 18, 2011. https://www.pbs.org/newshour/updates/health/jan-june11/flu_01-18.html. 
22. "Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection". The Journal of Experimental Medicine 208 (1): 181–93. January 2011. doi:10.1084/jem.20101352. PMID 21220454.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3023136
23. "A vaccine for all flu seasons". Spring 2011. http://whsc.emory.edu/home/publications/health-sciences/emory-health/spring11/a-vaccine-for-all.html. 
24. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. 2016 http://www.nature.com/articles/srep22666
25. Gallagher, James (29 July 2011). "'Super antibody' fights off flu". https://www.bbc.co.uk/news/health-14324901. 
26. "Scientists hail the prospect of a universal vaccine for flu". July 29, 2011. http://www.independent.co.uk/news/science/scientists-hail-the-prospect-of-a-universal-vaccine-for-flu-2327993.html. 
27. "Universal Flu Vaccine On The Horizon: Researchers Find 'Super Antibody'" The Huffington Post. July 28, 2011 http://www.huffingtonpost.com/2011/07/28/universal-flu-vaccine-antibody_n_912603.html
28. Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain http://mbio.asm.org/content/1/1/e00018-10.abstract
29. "Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes". Proceedings of the National Academy of Sciences of the United States of America 107 (44): 18979–84. November 2010. doi:10.1073/pnas.1013387107. PMID 20956293. Bibcode: 2010PNAS..10718979W.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2973924
30. "The Second Annual Einstein-Montefiore Presidential Lecture: William R. Jacobs, Ph.D., Lecture (3of3)". https://www.youtube.com/watch?v=sBsUUW3UrSw. 
31. Stadlbauer D, "Broadly protective human antibodies that target the active site of influenza virus neuraminidase" "Science", 2019 https://www.science.org/doi/10.1126/science.aay0678
32. Taylor A, "First Universal Flu Vaccine to Enter Phase 3 Trial" "The Scientist", 2018 https://www.the-scientist.com/news-opinion/first-universal-flu-vaccine-to-enter-phase-3-trial-65073
33. "Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population". Vaccine 32 (44): 5816–23. October 2014. doi:10.1016/j.vaccine.2014.08.031. PMID 25173483.  https://dx.doi.org/10.1016%2Fj.vaccine.2014.08.031
34. "Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol". Medicine (Baltimore) 96 (11): e6339. March 2017. doi:10.1097/MD.0000000000006339. PMID 28296763.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5369918
35. "The Search for a Universal Flu Vaccine Heats Up". JAMA 322 (20): 1942–1944. November 2019. doi:10.1001/jama.2019.16816. PMID 31693060.  https://dx.doi.org/10.1001%2Fjama.2019.16816
36. Clinical trial number NCT03058692 for "Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT03058692
37. Clinical trial number NCT03450915 for "A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT03450915
38. Phillipson, Josh. "BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate". BiondVax. http://www.biondvax.com/2020/10/biondvax-announces-topline-results-from-phase-3-clinical-trial-of-the-m-001-universal-influenza-vaccine-candidate/. 
39. "NIH begins first-in-human trial of a universal influenza vaccine candidate". April 3, 2019. https://www.nih.gov/news-events/news-releases/nih-begins-first-human-trial-universal-influenza-vaccine-candidate. 
40. Clinical trial number NCT03814720 for "Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine, VRCFLUNPF099-00-VP, in Healthy Adults" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT03814720
41. Bernstein, David I; Guptill, Jeffrey; Naficy, Abdollah; Nachbagauer, Raffael; Berlanda-Scorza, Francesco; Feser, Jodi; Wilson, Patrick C; Solórzano, Alicia et al. (January 2020). "Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial". The Lancet Infectious Diseases 20 (1): 80–91. doi:10.1016/S1473-3099(19)30393-7. PMID 31630990.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6928577
42. Nachbagauer, Raffael; Feser, Jodi; Naficy, Abdollah; Bernstein, David I.; Guptill, Jeffrey; Walter, Emmanuel B.; Berlanda-Scorza, Franceso; Stadlbauer, Daniel et al. (7 December 2020). "A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial". Nature Medicine 27 (1): 106–114. doi:10.1038/s41591-020-1118-7. PMID 33288923.  https://dx.doi.org/10.1038%2Fs41591-020-1118-7